RxDoctor Payments Data

Kathy Darnell

Family · Saint Joseph, MONPI 1144297367

Payments from drug & device makers

$8,156in general payments, 2019–2025

Across 385 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Viiv Healthcare Company$792
  • Gilead$407
  • Lilly USA, LLC$402
  • Novo Nordisk$387
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$8,10199%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,156 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$3,177
Medicare patients
96
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol117$126,267
OzempicSemaglutide64$81,855
BiktarvyBictegrav/Emtricit/Tenofov Ala20$79,868
TrulicityDulaglutide49$64,203
LinzessLinaclotide59$51,961
JanuviaSitagliptin Phosphate26$39,478
DovatoDolutegravir Sodium/Lamivudine11$37,484
JardianceEmpagliflozin20$27,456
XareltoRivaroxaban24$23,315
EliquisApixaban21$19,463
RexultiBrexpiprazole11$18,711
SymbicortBudesonide/Formoterol Fumarate25$14,377
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$10,838
MyrbetriqMirabegron14$8,810
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl39$8,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort, Bevespi Aerosphere$1,098$145,425153 claims
Novo NordiskOzempic$387$81,85564 claims
GileadBiktarvy$407$79,86820 claims
Lilly USA, LLCTrulicity$402$64,20349 claims
AbbVieLinzess, Lumigan$1,709$56,37176 claims
MerckJanuvia$178$39,47826 claims
Viiv Healthcare CompanyDovato$792$37,48411 claims
Boehringer IngelheimJardiance$106$27,45620 claims
Johnson & JohnsonXarelto$223$23,31524 claims
GSKAnoro Ellipta, Arexvy, Incruse Ellipta$12$22,61959 claims
Otsuka America Pharmaceutical, Inc.Rexulti$249$18,71111 claims
Astellas Pharma US IncMyrbetriq$81$8,81014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Saint Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →